U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07832032) titled 'Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine' on Sept. 11.
Brief Summary: There are still no reliable biomarkers for migraine; the diagnosis is based on symptomatology, and the pathogenesis remains largely a mystery. However, the past decade has seen a shift from a trial-and-error treatment strategy to a more biologically driven approach using CGRP-targeted drugs (gepants) and monoclonal antibodies (mAbs). This study aims to profile levels of perivascular and hypothalamic neuropeptides, as well as microRNA (miRNA) and neurotrophins, in individuals with migraine. The study builds on a previous pilot inve...